Analyst Price Target is $23.75
▲ +15.80% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Prime Medicine in the last 3 months. The average price target is $23.75, with a high forecast of $27.00 and a low forecast of $21.00. The average price target represents a 15.80% upside from the last price of $20.51.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Prime Medicine.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.